GO:0004915 interleukin-6 receptor activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004915 interleukin-6 receptor activity is a molecular function defined as combining with interleukin-6 and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.
• The receptor complex is built from the ligand-binding IL6R subunit and the signal-transducing gp130 subunit, and signaling can occur through membrane-bound or soluble IL-6R.
• IL-6 is a keystone cytokine in health and disease, driving both pro- and anti-inflammatory outputs depending on context.
• Dysregulated IL-6 receptor activity is implicated in cytokine storm syndromes, neuromyelitis optica spectrum disorder, MOG-IgG-associated disease, and metabolic/insulin sensitivity phenotypes.
• Soluble IL-6R generated by shedding or alternative splicing enables trans-signaling in cells that lack membrane-bound IL6R.
• CRISPR knockout, point-mutation, knock-in, and overexpression models allow causal dissection of IL6R, IL6ST, and downstream signaling components.
Description
Interleukin-6 receptor activity (GO:0004915) is the molecular function by which a cell binds interleukin-6 (IL-6) and converts that binding event into an intracellular signal across the plasma membrane. IL-6 is a pleiotropic cytokine that acts as a keystone regulator of inflammation, immunity, hematopoiesis, and metabolism, and its actions begin at the receptor. The receptor activity is therefore a central node for understanding how a single cytokine can produce context-dependent pro- and anti-inflammatory outcomes. Because IL-6 signaling is frequently dysregulated in human disease, the receptor function encoded by GO:0004915 is a major target of both mechanistic research and therapeutic blockade. The activity is not carried by a single polypeptide in isolation. IL-6 first engages the ligand-binding subunit IL6R, and the resulting complex recruits the signal-transducing subunit gp130 (IL6ST) to initiate downstream phosphorylation events. In addition, a soluble form of IL6R (sIL-6R) can bind IL-6 and stimulate cells that express gp130 but lack membrane-bound IL6R, a process known as trans-signaling. This duality helps explain why IL-6 can act on a broad range of cell types and why its receptor activity is relevant to diseases as diverse as neuromyelitis optica spectrum disorder and cytokine storm syndromes. For researchers, GO:0004915 provides a precise functional annotation for experiments that measure ligand binding, receptor complex assembly, and signal transmission. Studies of IL-6 receptor activity increasingly combine genetic perturbation with pathway readouts to determine which components are causally required in a given disease context. The sections below summarize the definition, mechanism, key genes, disease links, and experimental models used to study this activity.
interleukin-6 receptor activity At A Glance
| GO ID | GO:0004915 |
|---|---|
| GO term | interleukin-6 receptor activity |
| Ontology | molecular_function |
| Synonym | gp130; IL-6R; IL-6 receptor activity |
| Definition | Combining with interleukin-6 and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity. |
| Major function | Binds IL-6 and initiates transmembrane signaling to change cell activity |
| Ligand | Interleukin-6 (IL-6) |
| Core receptor subunits | IL6R (ligand-binding) and IL6ST/gp130 (signal-transducing) |
| Signaling modes | Classic signaling via membrane-bound IL6R and trans-signaling via soluble IL6R |
| Disease relevance | Cytokine storm syndromes, neuromyelitis optica spectrum disorder, MOG-IgG-associated disease, metabolic phenotypes |
What Is GO:0004915?
In plain terms, GO:0004915 interleukin-6 receptor activity describes the function of a receptor that binds interleukin-6 and then transmits a signal from the outside of the membrane to the inside of the cell, thereby initiating a change in cell activity. The official QuickGO definition is: Combining with interleukin-6 and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity. This is a molecular_function term, and its synonyms include gp130, IL-6R, and IL-6 receptor activity. The term captures the receptor's ligand-recognition and signal-transmission roles rather than any single downstream phosphorylation event.
Why Is interleukin-6 receptor activity Important in Cell Biology?
IL-6 receptor activity is important because it is the first committed step in a signaling axis that shapes inflammation, immunity, and metabolism, and because blocking this activity has proven therapeutic value in immune-mediated and hyperinflammatory diseases. IL-6 is described as a keystone cytokine in health and disease, meaning that its receptor activity influences many downstream processes and can shift between protective and pathogenic roles depending on context. Understanding GO:0004915 therefore helps researchers interpret how IL-6 contributes to disease and how receptor blockade or genetic perturbation alters cell behavior.
• IL-6 receptor activity initiates signaling by a keystone cytokine that regulates inflammation and immunity.
• The activity can proceed through membrane-bound IL6R (classic signaling) or soluble IL6R (trans-signaling), broadening the range of responsive cells.
• IL-6 has both pro- and anti-inflammatory properties, so receptor activity must be interpreted in a context-dependent manner.
• IL-6 receptor blockade is used in treatment-refractory MOG-IgG-associated disease and neuromyelitis optica spectrum disorders.
• IL-6 blockade is a strategy in cytokine storm syndromes, highlighting the clinical importance of this receptor activity.
• IL-6 is implicated in the pathophysiology of neuromyelitis optica spectrum disorder.
• Soluble IL-6 receptor levels can influence exercise responsiveness, glycemic control, and insulin sensitivity.
• IL-6 molecular pathophysiology has been recognized since early studies of its role in disease.
• The receptor activity is a tractable target for CRISPR-based causal studies of IL6R, IL6ST, and downstream components.
• Precise annotation of GO:0004915 supports reproducible functional genomics and drug-target research.
Molecular Mechanism of interleukin-6 receptor activity
Ligand recognition and initial binding
In simple terms: IL-6 first docks onto its specific receptor subunit, like a key finding its lock.
Interleukin-6 receptor activity begins when IL-6 binds the ligand-binding subunit IL6R. IL-6 is a pleiotropic cytokine whose actions depend on engagement of its receptor, and this binding event is the first step that commits the cell to a signaling response. The receptor activity is defined at the molecular level as combining with interleukin-6 and transmitting the signal across the membrane to initiate a change in cell activity, so ligand recognition is intrinsic to GO:0004915. Early work on IL-6 molecular pathophysiology established that IL-6 acts through a specific receptor system to influence cell behavior.
Receptor complex assembly with gp130
In simple terms: After IL-6 binds IL6R, the complex recruits a second subunit called gp130 to form the active signaling machine.
The IL-6/IL6R complex recruits the signal-transducing subunit gp130 (encoded by IL6ST), which is required for transmitting the signal to the cell interior. The synonym list for GO:0004915 includes gp130, reflecting the historical and functional association of gp130 with this receptor activity. Assembly of the ligand-receptor-gp130 complex is the structural basis for the transmembrane signaling event described in the definition. Because gp130 is a shared subunit, the receptor activity connects IL-6 to broader cytokine signaling networks.
Classic signaling versus trans-signaling
In simple terms: Cells with the full receptor respond directly, while cells lacking it can still respond if a soluble version of the receptor captures IL-6 for them.
IL-6 receptor activity can occur in two principal modes. In classic signaling, membrane-bound IL6R on the cell surface binds IL-6 and presents it to gp130. In trans-signaling, a soluble form of IL6R (sIL-6R) binds IL-6 and stimulates cells that express gp130 but lack membrane-bound IL6R. The soluble IL-6 receptor and related proteins are generated by shedding or alternative splicing and expand the range of cells that can respond to IL-6. This duality is central to understanding why IL-6 receptor activity has broad physiological and pathological effects.
Signal transmission and cellular outcome
In simple terms: Once the receptor complex is assembled, it sends a signal inside the cell that changes what the cell does.
The defining output of GO:0004915 is transmission of a signal from one side of the membrane to the other to initiate a change in cell activity. IL-6 signaling through its receptor influences inflammation, immunity, and metabolism, and the cytokine is considered a keystone in health and disease. The pro- and anti-inflammatory properties of IL-6 mean that the same receptor activity can drive different cellular outcomes depending on context. Clinically, interrupting this signal transmission with receptor blockade alters disease course in inflammatory and autoimmune conditions.
Regulation by soluble receptor and ligand availability
In simple terms: The amount of IL-6 and the amount of soluble receptor in the environment can dial the signal up or down.
The activity of the IL-6 receptor system is influenced by the availability of both ligand and soluble receptor. Soluble IL-6R and related proteins modulate IL-6 responses and are themselves regulated by shedding and alternative splicing. In humans, gut microbiome-adipose crosstalk has been reported to modulate soluble IL-6 receptor and influence exercise responsiveness in glycemic control and insulin sensitivity, illustrating that sIL-6R levels can have systemic metabolic consequences. These observations indicate that GO:0004915 is not a fixed switch but a tunable function sensitive to the extracellular milieu.
Key Genes Involved in GO:0004915 interleukin-6 receptor activity
The genes and proteins most directly associated with interleukin-6 receptor activity include the ligand IL6, the ligand-binding receptor subunit IL6R, the signal-transducing subunit IL6ST/gp130, and related regulators of soluble receptor generation and downstream signaling.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IL6 | Encodes interleukin-6, the ligand that binds the receptor | Central to studies of receptor activation and cytokine biology |
| IL6R | Encodes the ligand-binding subunit of the IL-6 receptor | Primary gene for GO:0004915; target of receptor blockade research |
| IL6ST | Encodes gp130, the signal-transducing subunit | Required for transmembrane signaling and complex assembly |
| ADAM17 | Protease implicated in shedding of membrane proteins including IL6R | Relevant to generation of soluble IL-6R and trans-signaling |
| ADAM10 | Protease implicated in ectodomain shedding | Relevant to soluble receptor biology and trans-signaling |
| SOCS1 | Negative regulator of cytokine signaling | Modulates intensity and duration of IL-6 receptor signaling |
| SOCS3 | Negative regulator of cytokine signaling | Modulates intensity and duration of IL-6 receptor signaling |
| JAK1 | Kinase that associates with cytokine receptor subunits | Downstream of receptor activation; relevant to signal transmission |
| JAK2 | Kinase that associates with cytokine receptor subunits | Downstream of receptor activation; relevant to signal transmission |
| TYK2 | Kinase that associates with cytokine receptor subunits | Downstream of receptor activation; relevant to signal transmission |
| STAT3 | Transcription factor activated downstream of IL-6 family signaling | Readout of receptor activity and cellular outcome |
| STAT1 | Transcription factor activated downstream of cytokine signaling | Readout of receptor activity and cellular outcome |
| IL6R soluble form (sIL-6R) | Soluble receptor generated by shedding or alternative splicing | Enables trans-signaling in cells lacking membrane IL6R |
| CRP | Acute-phase protein induced by IL-6 signaling | Clinical biomarker of IL-6 pathway activity |
| MOG | Autoantigen in MOG-IgG-associated disease | Disease context in which IL-6 receptor blockade has been studied |
| AQP4 | Autoantigen in neuromyelitis optica spectrum disorder | Disease context linked to IL-6 pathophysiology |
| IL6R blockade target (tocilizumab class) | Therapeutic monoclonal antibody target | Clinical relevance of IL-6 receptor activity |
How Is interleukin-6 receptor activity Regulated?
IL-6 receptor activity is regulated at multiple levels, including ligand availability, receptor expression, soluble receptor generation, and negative feedback. Soluble IL-6R and related proteins are produced by shedding and alternative splicing, which determines whether trans-signaling can occur in a given tissue. The pro- and anti-inflammatory properties of IL-6 imply that the receptor activity is subject to context-dependent control, with different downstream outputs depending on the cell type and environment. Negative regulators such as SOCS proteins modulate the intensity and duration of cytokine signaling downstream of receptor activation. In addition, systemic factors such as gut microbiome-adipose crosstalk can modulate soluble IL-6 receptor levels and thereby influence metabolic responses such as glycemic control and insulin sensitivity.
interleukin-6 receptor activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IL6R | Cytokine storm syndromes and hyperinflammation | IL6R knockout or blockade in immune cell models |
| IL6R | MOG-IgG-associated disease and neuromyelitis optica spectrum disorder | Patient-derived or autoimmune models with receptor blockade |
| IL6 | Inflammatory and autoimmune pathology | IL6 knockout and overexpression models |
| IL6ST | Cytokine signaling deficiency or dysregulation | IL6ST knockout and point-mutation models |
| sIL-6R regulators | Metabolic phenotypes including glycemic control and insulin sensitivity | Soluble receptor modulation models |
IL-6 receptor activity in cytokine storm syndromes
Cytokine storm syndromes are hyperinflammatory states in which excessive cytokine signaling contributes to tissue damage. IL-6 blockade is a recognized therapeutic strategy in these syndromes, directly implicating IL-6 receptor activity in disease pathogenesis and treatment. Because the receptor activity is the first step in IL-6 signal transmission, blocking it can attenuate the downstream inflammatory cascade. This clinical experience underscores why GO:0004915 is a high-priority functional annotation for translational research.
IL-6 receptor activity in neuromyelitis optica spectrum disorder and MOG-IgG-associated disease
IL-6 is implicated in the pathophysiology of neuromyelitis optica spectrum disorder, and IL-6 receptor blockade has been studied in treatment-refractory MOG-IgG-associated disease and neuromyelitis optica spectrum disorders. These findings link the molecular function described by GO:0004915 to autoimmune neurological disease. The rationale for targeting the receptor is that interrupting IL-6 signaling may reduce the inflammatory injury characteristic of these conditions. This makes the receptor activity a relevant focus for both mechanistic and therapeutic studies.
IL-6 receptor activity and metabolic phenotypes
Beyond immunology, soluble IL-6 receptor levels have been associated with exercise responsiveness in glycemic control and insulin sensitivity, with gut microbiome-adipose crosstalk implicated as a modulator. This suggests that IL-6 receptor activity, particularly trans-signaling via sIL-6R, can influence systemic metabolism. The finding expands the disease relevance of GO:0004915 beyond classical inflammation to metabolic regulation.
IL-6 receptor activity in inflammation and immunity
IL-6 is a keystone cytokine in health and disease, and its receptor activity underpins both protective and pathogenic immune responses. The pro- and anti-inflammatory properties of IL-6 mean that the same receptor function can contribute to host defense or to tissue damage depending on context. Early work on IL-6 molecular pathophysiology established the broad disease relevance of this pathway. Together, these studies show that GO:0004915 is central to understanding cytokine-driven disease mechanisms.
From interleukin-6 receptor activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is IL6R required for IL-6-induced signal transmission? | IL6R knockout cell model |
| Does a specific IL6R residue mediate ligand binding? | IL6R point-mutation knock-in model |
| Can soluble IL6R drive trans-signaling in gp130-positive cells? | Soluble IL6R overexpression or knock-in model |
| Which downstream effectors are activated by the receptor? | Tagged knock-in of signaling components and pathway readouts |
| Does loss of gp130 abolish receptor activity? | IL6ST knockout model |
| Can receptor blockade phenocopy genetic loss of function? | IL6R knockout versus antibody blockade comparison |
How to Study the interleukin-6 receptor activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss of gene function | Testing requirement for IL6R or IL6ST in receptor activity |
| CRISPR point mutation | Effect of specific residues | Mapping ligand-binding or signaling interfaces |
| CRISPR knock-in | Tagged or variant protein expression | Tracking receptor complex assembly and localization |
| Overexpression | Gain of function | Testing soluble IL6R-driven trans-signaling |
| Transcriptional profiling | Changes in gene expression | Measuring downstream output of receptor activation |
| Protein assays | Receptor and soluble receptor levels | Quantifying shedding and ligand availability |
| Clinical outcome studies | Disease response to receptor blockade | Validating therapeutic relevance in inflammatory disease |
Genetic perturbation with CRISPR
CRISPR knockout, point mutation, knock-in, and overexpression models allow researchers to test whether IL6R, IL6ST, or downstream components are causally required for interleukin-6 receptor activity. Knockout of IL6R or IL6ST can abolish ligand-induced signaling, while point mutations can dissect specific binding interfaces. These approaches connect the molecular function annotated by GO:0004915 to observable cellular phenotypes.
Transcriptional and pathway readouts
Because IL-6 receptor activity initiates changes in cell activity, transcriptional readouts of downstream signaling are commonly used to measure the functional output. IL-6 signaling is linked to acute-phase and inflammatory gene programs, and STAT-family transcription factors are activated downstream of receptor engagement. Comparing wild-type and perturbed cells reveals which genes depend on the receptor activity.
Protein-level and soluble receptor measurements
Measuring soluble IL-6R and related proteins is important because trans-signaling can occur independently of membrane-bound IL6R. Protein-level assays can quantify receptor shedding and ligand availability, which together determine the effective level of receptor activity. Such measurements have been used to link soluble IL-6 receptor to metabolic phenotypes.
Clinical and translational assays
Clinical studies of IL-6 receptor blockade in cytokine storm syndromes and neuroinflammatory diseases provide translational validation of the receptor activity as a therapeutic target. These studies measure disease outcomes following interruption of the pathway, complementing mechanistic cell models. Together with basic signaling assays, they help define the disease contexts in which GO:0004915 is most relevant.
How CRISPR Can Be Used to Study GO:0004915 interleukin-6 receptor activity
Knockout
CRISPR knockout of IL6R or IL6ST provides a clean loss-of-function test for interleukin-6 receptor activity. If the receptor activity annotated by GO:0004915 is required for a phenotype, knockout cells should fail to respond to IL-6. This approach is widely applicable to immune, neurological, and metabolic cell models.
Point Mutation
Point mutations introduced by CRISPR allow precise dissection of residues involved in IL-6 binding or gp130 recruitment. Such models can separate ligand recognition from signal transmission, refining the functional annotation of GO:0004915. They are useful when complete knockout is too severe or when a specific interface is hypothesized.
Knock-in
Knock-in of tagged or variant receptor subunits enables tracking of complex assembly and localization. Knock-in models can also express soluble IL6R variants to study trans-signaling in a controlled genetic background. These tools help connect the molecular function to cell-type-specific outcomes.
Overexpression
Overexpression of IL6, IL6R, or soluble IL6R can amplify receptor activity and reveal gain-of-function phenotypes. This is particularly useful for studying trans-signaling, where soluble receptor availability is limiting. Overexpression models complement knockout studies by testing sufficiency rather than necessity.
How EDITGENE Supports interleukin-6 receptor activity Research
Researchers studying interleukin-6 receptor activity-related genes often need to determine whether a candidate gene is causally involved in ligand binding, receptor complex assembly, or downstream signal transmission. EDITGENE provides CRISPR-based cell model services that support this causal dissection across knockout, point-mutation, knock-in, and overexpression formats.
Contact EDITGENE today to design your custom CRISPR model for interleukin-6 receptor activity research.
Frequently Asked Questions About interleukin-6 receptor activity
What is interleukin-6 receptor activity?
Interleukin-6 receptor activity (GO:0004915) is a molecular function defined as combining with interleukin-6 and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.
What is the GO ID for interleukin-6 receptor activity?
The GO ID is GO:0004915, and the ontology aspect is molecular_function.
What genes are involved in interleukin-6 receptor activity?
Key genes include IL6 (the ligand), IL6R (ligand-binding subunit), and IL6ST/gp130 (signal-transducing subunit), along with regulators of soluble receptor generation and downstream signaling.
What is the difference between classic signaling and trans-signaling?
Classic signaling uses membrane-bound IL6R, while trans-signaling uses soluble IL6R to stimulate cells that express gp130 but lack membrane-bound IL6R.
Why is IL-6 considered a keystone cytokine?
IL-6 is described as a keystone cytokine in health and disease because its receptor activity influences many physiological and pathological processes.
Which diseases are linked to IL-6 receptor activity?
IL-6 receptor activity is linked to cytokine storm syndromes, neuromyelitis optica spectrum disorder, MOG-IgG-associated disease, and metabolic phenotypes such as glycemic control and insulin sensitivity.
How is IL-6 receptor activity studied in the lab?
Researchers use CRISPR knockout, point mutation, knock-in, and overexpression models together with transcriptional and protein readouts to study this activity.
What are the synonyms for GO:0004915?
The synonyms are gp130, IL-6R, and IL-6 receptor activity.
Can soluble IL-6 receptor influence metabolism?
Yes, gut microbiome-adipose crosstalk has been reported to modulate soluble IL-6 receptor and influence exercise responsiveness in glycemic control and insulin sensitivity.
How does IL-6 receptor blockade work in disease?
IL-6 receptor blockade interrupts signal transmission and has been studied in treatment-refractory MOG-IgG-associated disease, neuromyelitis optica spectrum disorders, and cytokine storm syndromes.
Conclusion
Interleukin-6 receptor activity (GO:0004915) is a molecular function that begins with IL-6 binding and ends with a change in cell activity, mediated by the IL6R and gp130 receptor subunits and modulated by soluble receptor forms. Its importance spans inflammation, immunity, neurology, and metabolism, with clinical relevance demonstrated by IL-6 receptor blockade in cytokine storm syndromes and neuroinflammatory diseases. Continued research using CRISPR-based models will help clarify how this receptor activity contributes to health and disease.
References
- 1. Ringelstein M et al.. 2022. Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG-Associated Disease and Neuromyelitis Optica Spectrum Disorders.. Neurol Neuroimmunol Neuroinflamm 9(1) PMID: 34785575
- 2. Scheller J et al.. 2011. The pro- and anti-inflammatory properties of the cytokine interleukin-6.. Biochim Biophys Acta 1813(5):878-88 PMID: 21296109
- 3. Barrett D. 2024. IL-6 Blockade in Cytokine Storm Syndromes.. Adv Exp Med Biol 1448:565-572 PMID: 39117839
- 4. Hunter CA et al.. 2015. IL-6 as a keystone cytokine in health and disease.. Nat Immunol 16(5):448-57 PMID: 25898198
- 5. Wang Y et al.. 2025. Gut microbiome-adipose crosstalk modulates soluble IL-6 receptor influencing exercise responsiveness in glycemic control and insulin sensitivity.. Cell Metab 37(12):2323-2341.e6 PMID: 41260222
- 6. Sehgal PB. 1990. Interleukin-6: molecular pathophysiology.. J Invest Dermatol 94(6 Suppl):2S-6S PMID: 2191052
- 7. Fujihara K et al.. 2020. Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology.. Neurol Neuroimmunol Neuroinflamm 7(5) PMID: 32820020
- 8. Rose-John S. 2015. The soluble interleukin-6 receptor and related proteins.. Best Pract Res Clin Endocrinol Metab 29(5):787-97 PMID: 26522462
